News

Horizon secured an unsolicited and highly conditional proposal from Abcam. Abcam has offered £1.81 per Horizon share, which represents a premium of only 25.7% to its share on 1

monARC's multi-disciplinary team of drug developers and technology experts have built disease-specific patient network applications and online tools that prequalify and engage patients during protocol development prior to

Casma is pioneering novel strategies to boost autophagy to arrest or reverse the progression of rare genetic diseases and broader pathologies, including neurodegeneration. Autophagy is the natural process

The deal now includes shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine. Merck and Moderna will now jointly advance mRNA-5671 in human studies, and

Novartis firm Sandoz received a complete response letter (CRL) regarding the BLA for biosimilar rituximab and is planning to conduct further discussions with FDA to bring the medicine to

Delian Capital led the investment round with participation from existing and new investors including OnKure management. The investment will help the company aggressively accelerate its research and development

Merck executive board member and Merck healthcare CEO Belén Garijo said: "Our collaboration with SFJ illustrates Merck KGaA, Darmstadt, Germany's increasing focus on strategic partnering in order to

Janssen Biotech is one of the Janssen Pharmaceutical Companies owned by Johnson & Johnson. BeneVir is a portfolio company within HC2’s Pansend Life Sciences subsidiary. BeneVir is currently

This is the first of what the Company expects will be a series of product acquisitions designed to generate revenue and strengthen its financial position. Vivus CEO John